Edwards Lifesciences Held-to-Maturity Debt Securities - Fair Value decreased by 16.5% to $39.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 26.2%, from $53.00M to $39.10M.
A fair value significantly lower than amortized cost may indicate potential credit impairment or interest rate risk, even if the bank intends to hold them.
This is the fair value of debt securities that the company has the positive intent and ability to hold until maturity. W...
Required disclosure for all banks holding HTM securities under GAAP.
htm_debt_securities_fair_value| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.00M | $83.00M | $160.00M | $65.20M | $123.00M | $28.00M | $28.10M | $28.00M | $56.00M | $53.40M | $50.50M | $53.00M | $44.70M | $46.80M | $39.10M |
| QoQ Change | — | +137.1% | +92.8% | -59.3% | +88.7% | -77.2% | +0.4% | -0.4% | +100.0% | -4.6% | -5.4% | +5.0% | -15.7% | +4.7% | -16.5% |
| YoY Change | — | — | — | +86.3% | +48.2% | -82.5% | -56.9% | -77.2% | +100.0% | +90.0% | +80.4% | -5.4% | -16.3% | -7.3% | -26.2% |